NDUFB6
ENSG00000165264
Target class
Enzyme
Chromosome
9
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- NDUFB6
- Gene name
- NADH:ubiquinone oxidoreductase subunit B6
- Gene symbol
- NDUFB6
- Protein name
- NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 (Complex I-B17) (CI-B17) (NADH-ubiquinone oxidoreductase B17 subunit)
- B17
- CI
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 85.19
- Tissue specificity (Gini)
- 0.14
- Tissue specificity (tau)
- 0.436
- KEGG gene identifiers
- hsa:4712
- Protein interaction confidence
- 0.936867
- Protein interaction partners
- 98
- R-HSA-611105
- R-HSA-6799198
- R-HSA-9837999
- End position
- 32573184
- Start position
- 32553001
- Chromosome
- 9
- Strand
- Reverse
- Mitochondrion inner membrane
- Single-pass membrane protein
- Matrix side .
- Mitochondria
- Nucleoplasm
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.435902
- Expression inequality (Gini)
- 0.140439
Expression in transcripts per million
- Testis
- 85.19
- Heart - Left Ventricle
- 74.43
- Cells - Cultured fibroblasts
- 67.93
- Heart - Atrial Appendage
- 65.55
- Kidney - Medulla
- 65.49
Expression in transcripts per million
- Testis85.19
- Heart - Left Ventricle74.43
- Cells - Cultured fibroblasts67.93
- Heart - Atrial Appendage65.55
- Kidney - Medulla65.49
- Brain - Frontal Cortex (BA9)63.19
- Cells - EBV-transformed lymphocytes61.97
- Brain - Cerebellar Hemisphere61.6
- Brain - Nucleus accumbens (basal ganglia)60.65
- Brain - Spinal cord (cervical c-1)59.38
- Artery - Aorta59.27
- Nerve - Tibial59.02
- Artery - Coronary56.39
- Fallopian Tube55.91
- Artery - Tibial55.26
- Brain - Anterior cingulate cortex (BA24)54.2
- Pituitary53.5
- Muscle - Skeletal53.45
- Brain - Hypothalamus53.34
- Uterus52.73
- Cervix - Endocervix51.77
- Brain - Cerebellum51.52
- Colon - Sigmoid51.12
- Thyroid50.49
- Adrenal Gland49.81
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0042775
- GO:0005739
- GO:0005743
- GO:0031966
- GO:0045271
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor